Baxter International Inc (NYSE:BAX) plans to acquire Gambro for $4B
Baxter International Inc (NYSE:BAX) revealed its plan to acquire Gambro, a privately held Swedish dialysis products maker in a deal valued at $4 billion.
The company’s CEO and chairman stated that BAX has made many innovations in dialysis. Their innovations include the development of peritoneal dialysis for the treatment of end-stage kidney disease patients in the home. He further stated that the acquisition of Gambro will expand the company’s dialysis line all around the globe by extending the BAX portfolio in the hemodialysis segment. This initiative will also help in raising product sales in reputable markets like Europe.
As per another statement, this agreement will also help Gambro to increase its presence in high-growth regions of Latin America and Asia-Pacific, where the company has gradually developed its peritoneal dialysis business.
Baxter is expected to complete this acquisition in the first half of the next year utilizing a mixture of debt and cash financing. The company which the Baxter International Inc (NYSE:BAX) is going to buy is supplier of dialysis products and technologies used in the process of hemodialysis and continuous renal replacement therapy. Gambro’s had sales of about $1.6 billion in the last year.
According to its CEO, this takeover will help the nephrology community, healthcare providers and patients who search for a complete dialysis offering of reputable products and therapies.
At the close of the trading day, Baxter International Inc. (NYSE:BAX) shares fell -0.46% to settle at $64.47. Intraday trading was between $64.22 – $65.14. In the past year, the stock has traded within a range of $47.55 – $68.91. The last session’s volume of 3.39 million shares was down from the average daily trading volume of 3.59 million shares.
Covidien plc (NYSE:COV) shares were down -0.54% to close at $57.62. The stock traded between $57.25 – $57.98 during the last trading session. In the last 12 months the shares have traded between $41.69 and $60.81. The last session’s volume of 2.22 million shares was a bit lower than their average daily trading volume of 2.56 million shares.
ICU Medical, Incorporated (NASDAQ:ICUI) shares in the last session were up +0.97% closing at $60.34. The stock traded in a range of $59.67 – $61.17. In the last year the stock has moved within a range of $42.54 – $362.79. The last session’s volume of 87,716 shares was up from their average daily trading volume of 64,677 shares.
Another rival company Cryolife Inc (NYSE:CRY), traded up +0.33% moving to $6.02. Intraday trading recorded the stock price in a range between $6.00 – $6.14. In the previous 52 weeks the price has traded between $4.08 – $7.27. The last session’s volume of 70,632 shares was up from their average daily trading volume of 58,085 shares.